Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: Non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect

Current Oncology Reports

Volumn 2, Issue 2, 2000, Pages 132-139

  Shimoni, Avichai ^a   Giralt, Sergio ^a   Khouri, Issa ^a   Champlin, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute GVHD; Chronic GVHD; Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia; Fludarabine

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOTRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

AGED; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0034157075     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-000-0084-y     Document Type: Article

References (54)

1. Thomas ED: Bone marrow transplantation for malignant disease. J Clin Oncol 1983, 1:517–531.
2. Thomas ED: The role of bone marrow transplantation for eradication of malignant disease. Cancer 1982, 49:1963–1969. DOI: 10.1002/1097-0142(19820515)49:10<1963::AID-CNCR2820491004>3.0.CO;2-A
3. Armitage JO: Bone marrow transplantation. N Engl J Med 1994, 330:827–838. DOI: 10.1056/NEJM199403243301206
4. Gale RP, Champlin RE: How does bone marrow transplantation cure leukemia? Lancet 1984, 2:28–30. DOI: 10.1016/S0140-6736(84)92009-9
5. Champlin R, Khouri I, Kornblau S, et al.: Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versusmalignancy. Curr Opin Oncol 1999, 11:87–95. DOI: 10.1097/00001622-199903000-00003
6. Bortin MM, Rimm AA, Saltztein EC: Graft versus leukemia: Quantification of adoptive immunotherapy in murine leukemia. Science 1973, 179:811–813. DOI: 10.1126/science.179.4075.811
7. Truiit R, LeFever A, Shih CY: Graft-versus leukemia reactions: Experimental models and clinical trials. In Progress in Bonemarrow Transplantation. Edited by Gale RP, Champlin RE, New York: Alan R Liss; 1987:219–232.
8. Horowitz M, Gale R, Sondel PM, et al.: Graft-versus leukemia reactions after bone marrow transplantation. Blood 1990, 75:555–562.
9. Goldman J, Gale R, Horowitz MM, et al.: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806–814.
10. Fefer A, Cheever MA, Greenberg PD: Identical-twin bone marrow (syngeneic) transplantation for hematologic cancers. J Natl Cancer Inst 1986, 76:1269–1271.
11. Gale RP, Horowitz MM, Ash RC, et al.: Identical twin bone marrow transplantation or leukemia. Ann Intern Med 1994, 120:646–652.
12. Weiden P, Flournoy N, Thomas E, et al.: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979, 300:1068–1073. DOI: 10.1056/NEJM197905103001902
13. Weiden P, Sullivan K, Flournoy N, et al.: Antileukemic effect of chronic graft-versus host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529–1532. DOI: 10.1056/NEJM198106183042507
14. Sullivan K, Storb R, Bucker CD, et al.: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989 320:828–834. DOI: 10.1056/NEJM198903303201303
15. Radich JP, Gehly G, Gooley T, et al.: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991, 77:874–878.
16. Collins RG, Rogers ZR, Bennet M, et al.: Hematologic relapse of chronic myelogenous leukemia following allogeneic transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992, 10:391–395.
17. Kolb HJ, Schattenberg A, Goldman JM, et al.: Graft-versusleukemia effect of donor lymphocyte infusions in marrow grafted patients. Blood 1995, 86:2041–2050. See annotation below.
18. Collins RH, Shpilberg O, Drobyski WR, et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433–444. These two publications are comprehensive reviews of donor lymphocyte infusions for treatment of relapsed malignancy following allogeneic BMT.
19. Tricot G, Vesole DH, Jagannath S, et al.: Graft-versus-myeloma effect: proof of principle. Blood 1996, 87:1196–1198.
20. Lokhorst HM, Schattenberg A, Comelissen JJ, et al.: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90:4206–4211.
21. Rondon G, Giralt S, Huh Y, et al.: Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996, 18:669–672.
22. Khouri I, Keating MJ, Korbling M, et al.: Transplant lite: Induction of graft vs malignancy using fludarabine based nonablative chemotherapy and allogeneic progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817–2824.
23. Ueno NT, Rondon G, Mizra NQ, et al.: Allogeneic peripheralblood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998, 16:986–993.
24. Porter D, Connor J, Van Deerlin V, et al.: Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999, 17:1234–1243.
25. Childs R, Clave E, Contentin N, et al.: Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999, 94:3234–3241.
26. Falkenberg JHF, Goselink HM, Van der Harst D, et al.: Growth inhibition of clonogenic leukemia precursor cells by minor histocompatibility antigen specific cytotoxic T lymphocytes. J Exp Med 1991, 174:27–33. DOI: 10.1084/jem.174.1.27
27. Molldrem JJ, Clave E, Jiang YZ, et al.: Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997, 90:2529–2534.
28. Ringden O, Horowitz M, Gale R, et al.: Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993, 270:57–60. International Bone Marrow Transplant Registry report summarizing treatment-related morbidity after allogeneic BMT for older adults with hematologic malignancy. DOI: 10.1001/jama.270.1.57
29. Klingemann H, Storb R, Fefer A, et al.: Bone marrow transplantation in patients aged 45 years and older. Blood 1986, 67:770–776.
30. Blume KG, Forman SJ, Nadermanee AP, et al.: Bone marrow transplantation for hematologic malignancies in patients age 30 and older. J Clin Oncol 1986, 4:1489–1492.
31. Bortin MM, Horowitz MM, Gale RP, et al.: Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 1992, 268:607–612. DOI: 10.1001/jama.268.5.607
32. Du W, Dansey R, Abella EM, et al.: Successful allogeneic bone marrow transplantation in selected patients over 50 years of age: a single institution experience. Bone Marrow Transplant 1998, 21:1043–1047. DOI: 10.1038/sj.bmt.1701210
33. Brincker H: Estimates of overall treatment results in acute non-lymphocytic leukemia based on age-specific rates of incidence and complete remission. Cancer Treat Rep 1987, 69:5–11.
34. Taylor PRA, Reid MM, Stark AN, et al.: De novo acute myeloid leukemia in patients over 55 years old: a population based study of incidence, treatment and outcome. Leukemia 1995, 9:231–237.
35. Hamblin TJ: Disappointments in treating acute leukemia in the elderly. N Engl J Med 1995, 332:1712–1713. DOI: 10.1056/NEJM199506223322511
36. Giralt S, Estey E, Albitar M, et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531–4536. Initial report of fludarabine-cytarabine-idarubicin non-myeloablative preparative regimen to achieve engraftment of allogeneic BMT and GVL effects in older or debilitated patients.
37. Antin JH, Ferrara JL: Cytokine dysregulation and acute graft-vs-host disease. Blood 1992, 80:2964–2968.
38. Hill GR, Crawford JM, Cooke KR, et al.: Total body irradiation and acute graft-vs-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90:3204–3213.
39. Slavin S, Nagler A, Naparstak E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998, 91:756–763. This report offers encouraging results with a reduced-toxicity preparative regimen for malignant and nonmalignant hematologic diseases.
40. Plunkett W, Sanders P: Metabolism and action of purine nucleoside analogs. Pharmacol Ther 1991, 49:239–245. DOI: 10.1016/0163-7258(91)90057-S
41. Estey E, Plunkett W, Gandhi V, et al.: Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993, 9:343–350. DOI: 10.3109/10428199309148532
42. Kornblau S, Gandhi V, Andreeff M, et al.: Clinical and laboratory studies of 2-chlorodeoxyadenosine ±cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 1996, 10:1563–1569.
43. Przepiorka D, Smith TL, Folloder J, et al.: Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999, 4:1465–1470.
44. Anderlini P, Przepiorka D, Lauppe J, et al.: Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 1977, 97:485–487. DOI: 10.1046/j.1365-2141.1997.302677.x
45. Bearman SI, Appelbaum FR, Buckner CD, et al.: Regimen related toxicities in patients undergoing bone marrow transplantation. J Clin Oncol 1988, 6:1562–8.
46. Craddock C, Szydlo R, Olavarria E, et al.: Leukemia free survival after allogeneic transplantation for chronic myeloid leukemia: effect of reclassifying responders to donor lymphocyte infusion as ‘currently free of leukemia.’ Blood 1997, 90:378b.
47. Giralt S, Cohen A, Mehra R, et al.: Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning [abstract]. Blood 1997, 90:417a.
48. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD: The systemic administration of intravenous melphalan. J Clin Oncol 1988, 6:1768–1782.
49. Li L, Keating MJ, Plunket W, Yang LY: Fludarabine-mediated repair inhibition of cisplatin induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Molecular Pharmacol 1997, 52:798–806.
50. Moreau P, Fiere D, Bezwoda WR, et al.: Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol 1997, 15:660–666.
51. Storb R, Yu C, Wagner J, et al.: Stable mixed hematopoietic chimerism in DLA-identical litter-mate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997, 89:3048–3054.
52. McSweeney P, Wagner J, Maloney D, et al.: Outpatient PBSC allografts using immunosuppression with low dose TBI before and cyclosporine and mycophenolate mofetil after transplant [abstract]. Blood 1998, 92(suppl 1):519a.
53. Kellmen E, Massazi T, Remenyi P, et al.: Reduction of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioning with a new, non-myeloablative drug combination. Bone Marrow Transplant 1998, 21:747–749. DOI: 10.1038/sj.bmt.1701167
54. Spitzer TR, McAfee S, Sakstein R, et al.: Induction of mixed chimerism and potent anti tumor responses following nonmyeloablative conditioning therapy and HLA-matched and mismatched bone marrow transplantation (BMT) for refractory hematologic malignancies [abstract]. Blood 1998, 92(suppl 1):519a.